Investigation of Cognitive Outcomes With Cannabidiol Oral Solution
Status:
Withdrawn
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the effects of GWP42003-P on cognition in pediatric
participants, aged 3 to 10 years, with Lennox-Gastaut Syndrome (LGS).